We overcome the biggest challenge for genetic medicines: Safe and effective delivery. We developed a field-leading proprietary technology for systemic nucleic acid delivery, based on scalable non-immunogenic materials. Our patented data-driven high-throughput screening platform allows us to screen novel nanocarrier formulations at unparalleled scale.
We use our cell-specific nanocarriers to develop mRNA and gene editing therapies for currently incurable diseases. Our pipeline includes immunotherapies, which we strive to advance rapidly into the clinic.
Location: United Kingdom, England, London
Employees: 1-10
Founded date: 2021
Investors 2
Date | Name | Website |
- | Y Combinat... | ycombinato... |
- | Aleka Capi... | alekacapit... |
Mentions in press and media 1
Date | Title | Description | Source |
24.03.2021 | Y Combinator’s biotech startups incubate a new generation of... | Medical and biotech had a strong showing at Y Combinator’s latest demo day, with nearly a dozen comp... | techcrunch... |